# US 2021/0060154 A1 · Vaccine composition and method of preventing porcine epidemic diarrhea virus infection in swine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060154 A1
- Document ID: US20210060154A1
- Status: Published application
- Kind: A1
- Application number: 17/000,377
- Filed: 2020-08-24
- Published: 2021-03-04
- Earliest claimed: 2019-09-02
- Assignees: Reber Genetics Co., Ltd.
- Applicants: Reber Genetics Co., Ltd.
- Inventors: Chia-Jung Chang; Jen-Yu Chang; Cheng-Xin Yang
- Web page: https://patentgrep.com/patent/US20210060154A1

## CPC

- A61K 39/225: Porcine transmissible gastroenteritis virus
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/552: {Veterinary vaccine}
- C12N 2770/20021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2770/20022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2770/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/20062: by genetic engineering
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

A vaccine composition includes a porcine epidemic diarrhea virus (PEDV) S1 spike protein having an amino acid sequence of SEQ ID NO: 1, and an inactivated porcine epidemic diarrhea virus (PEDV). The vaccine composition is used in a method of preventing PEDV infection in swine, whereby systemic Immunoglobulin G (IgG), Immunoglobulin A (IgA) and neutralizing antibody may be successfully induced by the vaccine composition, hence providing sufficient immune protection against PEDV.

## Claims

### Claim 1

A vaccine composition, comprising:
a porcine epidemic diarrhea virus (PEDV) S1spike protein having an amino acid sequence of SEQ ID NO: 1; and
an inactivated porcine epidemic diarrhea virus (PEDV).

### Claim 2 (depends on 1)

The vaccine composition according to claim 1, wherein a concentration of the PEDV S1 spike protein is in a range of about 15 μg/dose to about 75 μg/dose.

### Claim 3 (depends on 1)

The vaccine composition according to claim 1, wherein a concentration of the PEDV S1 spike protein is in a range of about 20 μg/dose to about 40 μg/dose.

### Claim 4 (depends on 1)

The vaccine composition according to claim 1, wherein a concentration of the PEDV S1 spike protein is about 30 μg/dose.

### Claim 5 (depends on 1)

The vaccine composition according to claim 1, wherein a concentration of the inactivated PEDV is in a range of about 1*106 of 50% tissue culture infective dose (TCID50)/dose to about 1*109 TCID50/dose.

### Claim 6 (depends on 1)

The vaccine composition according to claim 1, wherein a concentration of the inactivated PEDV is in a range of about 1*106 of TCID50/dose to about 1*107 TCID50/dose.

### Claim 7 (depends on 1)

The vaccine composition according to claim 1, wherein the PEDV S1 spike protein has a nucleotide sequence of SEQ ID NO: 2.

### Claim 8 (depends on 1)

The vaccine composition according to claim 1, wherein the PEDV S1 spike protein includes a signal peptide and has a nucleotide sequence of SEQ ID NO: 3.

### Claim 9 (depends on 1)

The vaccine composition according to claim 1, further comprising adjuvants, wherein a concentration of the adjuvants is in a range of 55% by weight to 65% by weight based on a total weight of the vaccine composition.

### Claim 10 (depends on 1)

The vaccine composition according to claim 1, wherein the inactivated PEDV has a nucleotide sequence of SEQ ID NO: 4.

### Claim 11 (depends on 1)

A method of preventing porcine epidemic diarrhea virus (PEDV) infection in swine, comprising:
vaccinating a pregnant sow with the vaccine composition of claim 1 at least three weeks prior to farrowing so as to confer immunity to its neonatal piglets.

### Claim 12 (depends on 11)

The method of preventing porcine epidemic diarrhea virus (PEDV) infection in swine according to claim 11, wherein the pregnant sow is vaccinated by administering a first dose of the vaccine composition eight weeks prior to farrowing, and administering a second dose of the vaccine composition five weeks prior to farrowing.

### Claim 13

A vaccine composition, comprising:
a modified porcine epidemic diarrhea virus (PEDV) S1 spike protein having a nucleotide sequence of SEQ ID NO: 3;
an inactivated porcine epidemic diarrhea virus (PEDV); and
mineral oil-based adjuvants.

### Claim 14 (depends on 13)

The vaccine composition according to claim 13, wherein a concentration of the mineral oil-based adjuvants is in a range of 55% by weight to 65% by weight based on a total weight of the vaccine composition.

### Claim 15 (depends on 13)

The vaccine composition according to claim 13, wherein the inactivated PEDV has a nucleotide sequence of SEQ ID NO: 4.
